Episode 240 - Inder Kaul - CMO at Draig Therapeutics

The BioHub Podcast hosts Dr. Inder Kaul, Chief Medical Officer at Draig Therapeutics, for a 27-minute conversation on neuropsychiatric drug development. Kaul brings substantial credentials: he played a key role in developing Cobenfy at Karuna Therapeutics and Bristol Myers Squibb, described as one of the most significant advances in schizophrenia treatment in decades. The episode explores several interconnected themes: the journey behind Cobenfy's development and what its success reveals about pursuing novel mechanisms in psychiatry; lessons Kaul has extracted from that experience and brought to his current role; and Draig's pipeline and strategic approach to neuropsychiatry. Specific focus areas include Draig's Phase 2 AMPA receptor modulator DT-101 for major depressive disorder, the therapeutic potential of targeting glutamate and GABA pathways in the CNS, and broader questions about what next-generation CNS drug development might look like. The framing emphasizes translating novel neuroscience into meaningful patient medicines and the clinical development expertise required to move differentiated science through to regulatory approval.

Verdict: A solid, focused interview with a credible expert on a timely topic that delivers on its promise, though the brief runtime and limited source detail prevent higher confidence in depth and clarity.

Science rubric

• Scientific accuracy n/a

  Source material does not provide enough detail about specific claims made during the conversation to assess accuracy; Cobenfy's significance in schizophrenia is stated but not substantiated in the notes.

• Clarity for non-experts n/a

  No information about how technical concepts (AMPA modulators, glutamate/GABA pathways) are explained or whether the host bridges jargon for general audiences.

• Sense of discovery 3/5 25%

  Guest has direct experience with a major approved drug (Cobenfy) and discusses emerging mechanisms (AMPA modulators, glutamate/GABA targeting) and Phase 2 programs, suggesting some fresh perspective on current CNS development landscape.

• Substance 3/5 25%

  Show notes indicate solid topical coverage (Cobenfy journey, mechanism discussion, pipeline details, industry lessons) but 27 minutes is relatively brief for deep exploration; likely contains meaningful content with some inevitable compress

• Delivers on its title 4/5 25%

  Title promises discussion of neuropsychiatric drug development evolution and translating neuroscience into medicines; notes confirm both themes are covered with concrete examples (Cobenfy, DT-101) and strategic context.

• Value for time 3/5 25%

  27 minutes is concise for the breadth of topics (Cobenfy history, mechanism discussion, Draig pipeline, industry outlook); likely well-paced but may sacrifice depth given the range covered.

How we score Science

Worth it if you follow CNS drug development, are curious about psychiatric medicine innovation, or want insider perspective on translating novel neuroscience mechanisms into approved therapies.

Based on the episode description. AI-generated; it can be wrong.